British Journal of Cancer · 2013 · 21 citations · 11 references
MedicinePreventive MedicineRadiologyCancer EpidemiologyCancer PreventionCancer ScreeningBreast ImagingCancer IncidenceCancer SurveillanceAge-specific Cancer RatesCancer Mortality RatesInterval Cancer DetectionMammographic Screening EpidemiologyMammographyRoutine ScreeningScreening Mammography
BACKGROUND: The introduction of two-view mammography at incident (subsequent) screens in the National Health Service Breast Screening Programme (NHSBSP) has led to an increased number of cancers detected at screen. However, the effect of two-view mammography on interval cancer rates has yet to be assessed. METHODS: Routine screening and interval cancer data were collated from all screening programmes in the United Kingdom for women aged 50-64, screened between 1 April 2003 and 31 March 2005. Interval cancer rates were compared based on whether two-view mammography was in use at the last routine screen. RESULTS: The reduction in interval cancers following screening using two-view mammography compared with one view was 0.68 per 1,000 women screened. Overall, this suggests the introduction of two-view mammography at incident screen was accompanied by a 15-20% reduction in interval cancer rates in the NHSBSP. CONCLUSION: The introduction of two-view mammography at incident screens is associated with a reduction in incidence of interval cancers. This is consistent with previous publications on a contemporaneous increase in screen-detected cancers. The results provide further evidence of the benefit of the use of two-view mammography at incident screens.
11
N J Wald, P J Major, Carole Parkes et al. · BMJ · 1995 · 148 citations
Prognosis and pathology of screen‐detected carcinomas
Irıs D. Nagtegaal, P C Allgood, Stephen W. Duffy et al. · Cancer · 2010 · 55 citations · Full text
Aggressiveness features and outcomes of true interval cancers
Laia Domingo, Jordi Blanch, Sònia Servitja et al. · European Journal of Cancer Prevention · 2012 · 47 citations
Medicine, Oncology, Breast Oncology +16